HLA- and genotype-based risk assessment model to identify infantile onset pompe disease patients at high-risk of developing significant anti-drug antibodies (ADA)

by | Feb 5, 2019 | 0 comments

Submit a Comment

Your email address will not be published. Required fields are marked *